Lyme Disease Diagnostic Devices Market By Product Type (Immunoassay Tests, PCR Tests, Microscopy-Based Tests, Lateral Flow Assays), By Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, PCR, Immunofluorescence Assay (IFA), Lateral Flow Immunoassays), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes), and By Region; Global Insights & Forecast (2023 ? 2030)

As per Intent Market Research, the Lyme Disease Diagnostic Devices Market was valued at USD 2.8 Billion in 2024-e and will surpass USD 3.7 Billion by 2030; growing at a CAGR of 4.9% during 2025-2030.

The Lyme Disease Diagnostic Devices market is critical in the early detection and treatment of Lyme disease, which is caused by Borrelia bacteria and transmitted through tick bites. With the increasing prevalence of Lyme disease, the demand for efficient and accurate diagnostic tools is on the rise. The market is driven by technological advancements in diagnostic devices, growing awareness about Lyme disease, and the need for faster, more reliable testing methods. Key players are investing in the development of innovative diagnostic solutions, which are expected to drive the market's growth in the coming years.

Immunoassay Tests Segment is Largest Owing to High Sensitivity and Popularity in Clinics

The immunoassay tests segment holds the largest share in the Lyme Disease Diagnostic Devices market. These tests are widely used due to their high sensitivity and ability to provide rapid results, making them popular in clinics and diagnostic laboratories. Immunoassays, including enzyme-linked immunosorbent assays (ELISA), detect antibodies produced by the body in response to infection. Their ability to detect both early and late stages of Lyme disease enhances their utility in clinical settings.

The growth of this segment is driven by the increasing demand for quick and reliable diagnostic solutions. Immunoassays are also cost-effective compared to other diagnostic methods, making them a preferred choice for healthcare providers. As the awareness of Lyme disease rises globally, the adoption of immunoassay tests is expected to continue expanding, especially in regions with high incidences of the disease.

PCR Tests Segment is Fastest Growing Owing to High Accuracy and Early Detection

Polymerase chain reaction (PCR) tests are the fastest-growing segment in the Lyme Disease Diagnostic Devices market due to their ability to detect the genetic material of Borrelia bacteria with high precision. PCR tests offer the advantage of identifying the disease in its early stages, even before the body has produced detectable levels of antibodies. This makes PCR an essential tool for early diagnosis, particularly in patients with nonspecific symptoms or during the early stages of infection.

The demand for PCR-based testing is growing rapidly as healthcare providers seek more accurate and rapid diagnostic tools. PCR tests are particularly valuable in regions with high Lyme disease prevalence, where early detection can significantly reduce the risks of complications. The development of portable and easy-to-use PCR devices further fuels the growth of this segment, making it accessible for point-of-care settings and rural areas.

ELISA Technology is Largest Owing to Cost-Efficiency and Widely Accepted Protocol

The Enzyme-Linked Immunosorbent Assay (ELISA) technology is the largest in the Lyme Disease Diagnostic Devices market due to its cost-effectiveness, ease of use, and widespread acceptance in clinical and laboratory settings. ELISA tests are commonly used for detecting antibodies against Borrelia bacteria, making them an essential diagnostic tool for Lyme disease. Their ability to detect both IgM and IgG antibodies allows for the identification of active infections and past exposures, thereby enhancing their utility.

As the most established technology for Lyme disease detection, ELISA enjoys wide adoption among diagnostic labs and hospitals. Its simplicity and affordability make it the go-to option for many healthcare providers, especially in regions with limited resources. The extensive use of ELISA for Lyme disease diagnosis is expected to continue, with improvements in test sensitivity and specificity driving its ongoing dominance in the market.

Hospitals Segment is Largest Owing to High Diagnostic Demand and Treatment Integration

The hospitals segment is the largest end-user category in the Lyme Disease Diagnostic Devices market. Hospitals are the primary healthcare settings for diagnosing and treating Lyme disease, as they have the necessary infrastructure, equipment, and medical professionals to manage complex cases. The demand for diagnostic devices in hospitals is driven by the need for accurate, rapid testing to initiate early treatment, which is crucial for preventing long-term health issues.

The increasing prevalence of Lyme disease, especially in endemic regions, has led to a surge in hospital-based diagnostic testing. Hospitals are adopting a range of diagnostic devices, from immunoassays to PCR tests, to ensure timely and accurate diagnosis. As awareness of Lyme disease grows and testing capabilities improve, the demand for diagnostic devices in hospitals is expected to remain strong.

North America Region is Largest Owing to High Incidence and Advanced Healthcare Infrastructure

North America is the largest region in the Lyme Disease Diagnostic Devices market, driven by the high incidence of Lyme disease, particularly in the United States. The region's advanced healthcare infrastructure, coupled with increasing awareness about Lyme disease, has led to a strong demand for diagnostic devices. North America also benefits from the presence of leading diagnostic device manufacturers, which ensures a steady supply of cutting-edge diagnostic technologies.

In addition to the high prevalence of Lyme disease in regions like the northeastern and midwestern United States, the availability of advanced diagnostic tools and widespread adoption of PCR and immunoassay tests have helped drive the market in this region. The United States, in particular, remains a key hub for Lyme disease diagnostics, with continuous improvements in diagnostic accuracy and early detection technologies expected to sustain growth in the North American market.

Leading Companies and Competitive Landscape

The Lyme Disease Diagnostic Devices market is characterized by the presence of several leading companies that are driving innovation in diagnostic technologies. Companies such as Abbott Laboratories, Bio-Rad Laboratories, and Thermo Fisher Scientific Inc. dominate the market with their wide range of diagnostic solutions, including immunoassay tests, PCR-based devices, and molecular diagnostic systems. These companies invest heavily in research and development to improve the accuracy, speed, and affordability of Lyme disease diagnostic tests.

The competitive landscape is also marked by strategic partnerships, mergers, and acquisitions aimed at expanding product portfolios and market reach. For instance, Thermo Fisher Scientific’s acquisition of several diagnostic companies has strengthened its position in the Lyme disease diagnostic market. Companies are also focusing on expanding their geographic presence, particularly in regions with high Lyme disease prevalence, to capitalize on the growing demand for diagnostic devices. As the market continues to evolve, the competition is expected to intensify, with players focusing on product differentiation, technological advancements, and expanding distribution networks.

Recent Developments:

• Abbott Laboratories launched a rapid diagnostic test for Lyme disease in 2023, enhancing point-of-care diagnosis and reducing wait times for results.
• Thermo Fisher Scientific Inc. received FDA approval for an advanced PCR-based Lyme disease test, improving the accuracy of early-stage Lyme disease detection.
• Bio-Rad Laboratories Inc. expanded its portfolio with a new line of immunoassay kits for Lyme disease, offering higher sensitivity and faster results for diagnostic labs.
• Cepheid Inc. announced a strategic partnership with diagnostic centers across the U.S. to improve Lyme disease testing accessibility in rural areas, leveraging their PCR technology.
• Hologic Inc. acquired a Lyme disease diagnostic company, enhancing its molecular diagnostic offerings and expanding its presence in the vector-borne disease diagnostics market.

List of Leading Companies:

• Abbott Laboratories
• Bio-Rad Laboratories Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Cepheid Inc.
• Becton Dickinson and Company (BD)
• BioMerieux SA
• Ortho Clinical Diagnostics
• F. Hoffmann-La Roche AG
• Trinity Biotech
• Quidel Corporation
• Hologic Inc.
• LabCorp

Report Scope: